Pricing Log in Create free account
Saturday 10 October 2026 Export all BMY data to Excel Powerpack

Bristol Myers Squibb Company

BMY Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

59.12 0.46 −0.77%
Market cap
$121.7B
P/E
13.0×
Fwd P/E
11.2×
Dividend yield
4.26%
F-score
8/9
Altman Z
2.14
Beneish M
−2.69
Dividend safety
63/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Bristol Myers Squibb Company (BMY) SEC filings, changes and red flags

Red flags

No red flags have been raised by Bristol Myers Squibb Company’s filings on file.

Filings

Form Period Filed What it reports Flags
10-Q Jun 30, 2026 P1I2: 11 added · 9 removed · 42 modified
P2I1A: no material changes, the filing says
8-K Jul 30, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K May 5, 2026 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026
8-K Apr 30, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 10 added · 8 removed · 52 modified
1A: 4 added · 1 removed · 51 modified
7: 55 added · 50 removed · 74 modified
8-K Feb 5, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jan 12, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Nov 17, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Oct 31, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Nov 3, 2025 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Oct 30, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
10-K Dec 31, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.